Supplied as a standardised multi-herb veterinary active pharmaceutical ingredient, Dahuang Jiedu Powder Veterinary Grade API is manufactured under a quality system aligned with veterinary Good Manufacturing Practice and the Chinese Veterinary Pharmacopoeia 2020 monograph for Dahuang Jiedu San. The material is released as a free-flowing yellow-brown to brownish-yellow powder and is available under manufacturer model codes DJD-VG-100 for oral solid dosage forms, DJD-VG-200 for injectable preparations, and DJD-VG-300 for water-soluble powders, granules, and feed premix. It differs from mechanically pulverised herbal powders because it is standardised by high-performance liquid chromatography to total anthraquinone markers—aloe-emodin, rhein, emodin, and chrysophanol—and to baicalin and berberine hydrochloride. Representative release limits include total anthraquinones not less than 1.5% calculated as aloe-emodin, baicalin not less than 2.0%, and berberine hydrochloride not less than 1.0%. The low-fibre extract matrix permits direct compression, capsule filling, wet granulation, sterile filtration after reconstitution, and aqueous dispersion. The API is intended solely as a starting material for licensed veterinary pharmaceutical manufacture; it is not a finished dose for direct administration.

What Specifications Define Acceptance for Veterinary API Release?

Acceptance testing follows a combination of botanical monograph identity methods and quantitative marker assays. Identification of the component herbs is performed by thin-layer chromatography against reference materials for Rhei Radix et Rhizoma, Scutellariae Radix, and Phellodendri Cortex. Chromatographic assay is conducted on an octadecylsilyl C18 column, 250 × 4.6 mm, 5 µm, with a mobile-phase gradient of acetonitrile and 0.1% phosphoric acid; detection is set at 254 nm for anthraquinone markers and 280 nm for baicalin and berberine hydrochloride. System suitability requires resolution between emodin and chrysophanol of not less than 1.5 and tailing factor not more than 2.0. The finished API is controlled for moisture, ash, particle size, heavy metals, microbial burden, and marker content. Endotoxin limits are applied only to the injection-grade model because endotoxin is not destroyed by the anthraquinone system and may co-precipitate with lipopolysaccharide under acidic conditions.

Tablet compaction of DJD-VG-100 at a typical unit dose of 100 mg per tablet is performed on a rotary tablet press with compression force of 12–18 kN and pre-compression of 2–4 kN. Feed-frame speed and die-fill density are adjusted to maintain tablet hardness between 60 N and 90 N; the extract tends to soften when residual moisture exceeds 5.0%. Disintegration in water at 37°C should remain within 15 min when tested according to CP 2020 0921. For capsule production, blending with 0.5–1.0 wt% colloidal silicon dioxide and 0.5–2.0 wt% magnesium stearate is performed for no longer than 15 min to prevent marker demixing. Tablet ejection force is maintained at 8–12 kN; ejection load rises sharply when ambient relative humidity exceeds 60%, increasing punch-face picking and edge capping.

When Sterile Filtration Becomes the Rate-Limiting Step for Injectable Solutions

Injection-grade DJD-VG-200 is supplied as a sterile-filterable powder with residual moisture ≤ 3.0%. Reconstitution in water for injection at 100 g/L produces a dark amber solution with pH 5.5–6.5 and viscosity of 2.1–2.8 mPa·s at 25°C. The critical processing window is the filtration cascade. Because the extract retains residual polysaccharides and glycopeptides, the 0.22 µm polyethersulfone membrane loading capacity has been observed to fall to 10–25 L/m² depending on lot-to-lot pectin content; a 0.45 µm polypropylene prefilter is required to prevent blinding. Differential pressure across the sterile membrane is maintained below 1.0 bar (100 kPa) to avoid gel-layer compaction. Flux decline of 40–60% during the first 30 min is typical, after which flux stabilises if retentate temperature is held at 20–25°C. Terminal sterilisation by autoclaving at 121°C for 15 min is not recommended for aqueous solutions because marker degradation increases and pH shifts by 0.5–1.0 units; aseptic filtration is the preferred route. For a 5 mg/kg dose, the manufacturing endotoxin limit is calculated at 0.5 EU/mg; the specification of 0.25 EU/mg provides a safety margin. Published data for this specific product at higher reconstituted concentrations are limited; finished-dose manufacturers should verify filter capacity with production-scale lots before routine batch sizing.

Granulation of DJD-VG-100 in a 25 L high-shear mixer uses 2.5–5.0 wt% povidone K30 dissolved in 60–70% ethanol. Free-water addition beyond 8.0 wt% of dry granulate mass produces paste formation because the extract becomes tacky above 60% relative humidity. The granules are passed through a 1.0 mm sieve and dried at 50–55°C to final moisture ≤ 3.0%. Feed premix with DJD-VG-300 is produced at inclusion rates of 2–10 g/kg in a double-cone blender operating at 30 rpm for 10 min; batch uniformity is accepted when the coefficient of variation for baicalin or berberine content is ≤ 5.0%. Oral solutions are prepared at 10–20 g/L in phosphate-buffered water adjusted to pH 5.5–6.5, with 0.1% sodium benzoate as preservative; passage through a 0.45 µm clarifier is recommended before storage vessels. For injectable solution manufacture, the solution is aseptically filtered through a sterile 0.22 µm membrane and filled into depyrogenated amber vials under grade A laminar flow.

Comparative Powder Morphology and API-Grade Differentiation

The primary difference from conventional Dahuang Jiedu San powder is the removal or control of the native plant cell wall matrix. Crude pulverised herb powders have a broad particle-size distribution, often above 180 µm, and high fibre content; they are not directly compressible and retain significant microbial loads. The veterinary API grade is spray-dried or dispersed on a non-reactive carrier, giving a D90 of ≤ 150 µm for oral solid grade and ≤ 25 µm for injection grade. This controlled particle morphology reduces segregation in low-dose premixes and improves content uniformity. Compared with non-veterinary botanical extracts, the veterinary API grade is tested for veterinary residual solvent limits, target-animal safety data, and microbiological limits based on animal dosing rather than human food-supplement practice. However, published comparative bioequivalence data against other Dahuang Jiedu powder sources are limited; equivalence must be demonstrated by the finished-dose manufacturer for each target species and dosage form.

Batch-to-Batch Marker Variability Is Managed Through Multi-Lot Blending

Because Dahuang Jiedu Powder is a botanical compound rather than a single chemical entity, anthraquinone content can shift with harvest season, drying method, and storage temperature. Manufacturing trend data for single-lot extracts show total anthraquinones varying around the 1.5% release threshold by 0.3–0.5 percentage points, making multi-lot blending necessary to maintain analytical batch-to-batch consistency. Blending is performed in a 2000 L ribbon mixer with a fill ratio of 0.6–0.7 and mixing time of 20–30 min; blend homogeneity is verified by sampling 10–12 locations and accepting a relative standard deviation ≤ 5.0% for aloe-emodin, baicalin, and berberine hydrochloride. If berberine hydrochloride content falls below 0.8% in any incoming lot, the lot is rejected or diverted to non-injection oral grades. The API is stored in double-lined polyethylene bags inside fibre drums at 15–25°C and ≤ 60% relative humidity. Under these conditions, marker retention in accelerated stability studies conducted at 40°C and 75% relative humidity for 6 months remains within 90–105% of initial assay, while the colour darkens slightly. At moisture above 6.0%, particle caking is observed in the oral solid grade, and friable granules become prone to surface picking during tablet compression.

Operational boundaries are set by the extract’s hygroscopicity and pH sensitivity. The powder should not be dry-blended at relative humidity above 60%, and aqueous solutions should not be combined with amine-bearing additives or strong oxidising agents because the anthraquinone system can undergo redox interactions that alter marker recovery. Storage beyond 24 h at 25°C in untreated drinking water is not supported by published stability data; solutions exposed to direct sunlight show a 10–15% loss in total anthraquinone markers after 8 h. In feed processing, extrusion above 85°C may reduce marker content by more than 10% and is not recommended without stability verification. The material is not intended for use in species or dose forms not approved by the local veterinary regulatory authority.